First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.
Single-agent immunotherapy offers endometrial cancer patients longer survival than chemotherapy with milder side effects.
A need exists for first-line chemotherapy-free options in advanced or recurrent endometrial cancer. First-line pembrolizumab showed a statistically significant and clinically meaningful improvement in progression-free survival, with lower frequency of overall and grade 3 or above treatment-related adverse events.
What the study was
- Study design
- Randomized controlled trial
- Sample size
- 150
- Category
- Other
- Maturity
- Potentially Practice-Changing
- Journal
- Lancet
Why it surfaced
Randomized controlled trial; human evidence; PubMed abstract reviewed; conservative rubric score 9/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.